Quarterly report pursuant to Section 13 or 15(d)

STOCKHOLDERS' DEFICIENCY (Details)

v2.4.0.6
STOCKHOLDERS' DEFICIENCY (Details) (USD $)
3 Months Ended 9 Months Ended
Jun. 30, 2012
Jun. 30, 2011
Jun. 30, 2012
Jun. 30, 2011
Stock-based compensation expenses $ 340,200 $ 380,000 $ 1,010,700 $ 1,225,400
Neurometric Services Revenue [Member]
       
Stock-based compensation expenses 2,500 2,500 7,600 7,600
Research [Member]
       
Stock-based compensation expenses 24,000 28,900 75,200 170,400
Product Development [Member]
       
Stock-based compensation expenses 19,000 16,900 53,600 50,800
Selling and Marketing Expense [Member]
       
Stock-based compensation expenses 49,500 48,800 147,400 160,200
General and Administrative Expense [Member]
       
Stock-based compensation expenses $ 245,200 $ 282,900 $ 726,900 $ 836,400